the Abbott IMx automated immunoassay system. Cur rently, the IMx CA 125 assay is not available for sale in the US. The probe/electrode assembly delivers 150 /xL of serum sample, specimen diluent (buffered sheep serum with protein stabilizers), and anti-CA 125 (sheep, polyclonal) antibody-coated microparticles in buffer to the incubation well of the reaction cell. After formation of antibody-antigen complex during incuba tion, an aliquot is transferred to the glass fiber matrix to which the microparticles are irreversibly bound, and the matrix is washed to remove unbound materials.
The OC 125 (mouse, monoclonal)-alkaline phos phatase conjugate in buffer (>0.1 mg/L) is dispensed onto the matrix to bind to the antibody-antigen com plex. After another wash, 4-methylumbelliferyl phos phate substrate (1.2 mmol/L in buffer) is added to the matrix and the fluorescent product is measured by the MEIA optical assembly. Total procedure time is 42 min. Specimens with a CA 125 assay value >600 kAU/L are automatically flagged with the code ">600." In this case, a manual dilution procedure of the speci men can be performed with the IMx CA 125 specimen diluent before pipetting the sample into the sample well. Six IMx CA 125 calibrators (0, 15, 50, 125, 375, and 600 kAU/L) are processed, and the point-to-point curve calculated by the built-in algorithm is stored. A Mode 1 calibrator of 50 kAU/L for system calibration verification and curve adjustment within the manufac turer's specified preset limits is run with each series of 24 tests.
The IMx CA 125 assay has recently been improved by recalibration and reformulation. To more closely match the Centocor RIA and RIA II assays and allow for full market entry, Abbott has adjusted the CA 125 assay standards (~35%), increased the protein concen trations of accessory and specimen diluents, and im proved the manufacturing process of the micropar ticles .
The Abbott CA 125 RIA Monoclonal is a double determinant one-step sandwich-type IRMA identical to the Centocor CA 125 RIA procedure serving as the comparison method. This kit includes the monoclonal OC 125 antibody both as capture and tracer in a simultaneous sandwich format (3) . According to the manufacturer's instructions, 100-/xL aliquots of five CA 125 calibrators (range 7-500 kAU/L) or 100 fiL of serum specimen are pipetted into tubes and incubated for 20 h at room temperature, together with OC 125-coated beads and 125I-labeled OC 125. After the beads are washed to remove unbound materials, the radioac tivity bound to the coated carriers, which is propor tional to the concentration of CA 125 in the serum specimen, is counted in a gamma counter. Results of this assay were calculated with the 1224 MultiCalc Program (Wallac Oy, Turku, Finland). The minimum detectable concentration of this test is -7.0 kAU/L.
Analytical evaluation. The performance of the IMx CA 125 MEIA was assessed by evaluating (a) the detection limit of the assay (defined as the lowest concentration of CA 125 that is >2 SD above the mean signal for 20 replicate determinations of the zero cali brator); (b) within-assay precision (three serum speci mens with CA 125 concentrations 17-240 kAU/L in 20 replicates assayed three times) and between-assay pre cision (the same serum specimens run in duplicate in 73-79 consecutive assays run over >90 days), as well as construction of a precision profile (covering the entire dynamic range of both assay procedures and derived from the duplicate measurements of unknowns processed during the present study); and (c) accuracy testing, comprising checks of linearity and influence of supplied specimen diluent buffer (determined with three serially diluted serum specimens with high CA 125 concentrations); tests of the occurrence of a highdose hook effect (defined as an analytical response below that of the highest calibrator of 600 kAU/L, in two undiluted specimens with a very high concentra tion of CA 125); and assessment of CA 125 measure ments made with IMx and RIA in serum specimens from three ovarian cancer patients for possible inter ference from HAMA before and after OC125 F(ab')2 injection ( (Fig. 2A, 2B) ( Table 2 (Table 3) .
Ovarian carcinoma. In patients with malignant ep ithelial tumors of the ovary we used the CA 125 IMx to assay sera collected before primary treatment (Table 3) or during clinical follow-up (Table 4) the 61 serum specimens with CA 125 values >100 kAU/L and collected from pretreatment patients with ovarian carcinoma (Fig. 2C) .
Other malignant diseases. No remarkable differ ences were observed between the respective positivity rates obtained for blood samples collected from the pretreatment patients with other gynecologic and nongynecologic malignancies (Table 3) . Fig. 3B) and different (AUCxm* > AUCria) for ROC curves of healthy perimenopausal controls vs patients with ovarian cancer (Fig. 3A) .
The 83, Fig. 3B ) obtained with the group of benign ovarian diseases as controls suggest a similar perfor mance of the two assay procedures, despite a report (20) that quantification of CA 125 is adequate for discriminating malignant from benign pelvic masses in postmenopausal women.
Another change made in the improved IMx CA 125 assay concerned the increased protein concentration of the specimen diluent buffer. This has been reported to improve dilution linearity (15), although we still ob served nonlinear responses at higher dilutions (Table  1) . Thus, the diluent buffer needs further improvement to overcome this matrix effect.
The improved IMx CA 125 test demonstrates an outstanding precision profile across the entire dynamic range and particularly in the very low concentration range. Consequently, if one decides to assay a serum specimen only once, the IMx assay is obviously the most suited candidate. The high precision obtained with the IMx MEIA system is probably due to the use of a closed system, because only reagents developed specifically for the instrument are applicable, with very strict test procedures. Another possibility for increased precision with the IMx kit may be the additional inclusion of a polyclonal anti-CA 125 serum as the capture antibody. Such an antibody may have an higher affinity for the CA 125 antigen than the mono clonal OC 125 used as signal antibody in the IMx assay and as both capture and signal antibody in the other CA 125 assay procedures.
